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Abstract
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-
GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study,
we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-
based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans’ algorithm and 11 (28%)
were of the GCB-type according to Choi’s algorithm. According to both Hans’ and Choi’s algorithms, the non-GCB type was
predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB
subgroups (Hans’ algorithm: p= 0.57, Choi’s algorithm: p= 0.99). Furthermore, the prognosis of localized nasal/paranasal
DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered
poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/
paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show
poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of
subclassification.
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Introduction
Although heterogeneous in nature, diffuse large B-cell lympho-
ma (DLBCL) can be classified into 2 distinct subtypes on the basis
of genetic profiling: the germinal center B-cell-like (GCB)
phenotype and the non-germinal center B-cell-like (non-GCB)
phenotype [1,2,3]. Notably, patients belonging to the former
group have a better prognosis than those belonging to the latter
group. Hans et al. reported that these DLBCL subtypes can be
easily distinguished on the basis of immunohistological staining for
CD10, BCL6, and MUM1 proteins [2]. Later, Choi et al. added 2
new antibodies, FoxP1 and GCET1 [4], and Choi’s algorithm is
reported to achieve better prognostic classification than Hans’
algorithm [5]. Extranodal non-GCB-like DLBCL is generally
characterized by poor prognosis regardless of its localized disease,
but localized primary non-tonsillar oral DLBCL exhibits favorable
prognosis even in cases of the non-GCB subtype [6]. Nasal/
paranasal DLBCL is uncommon, and the GCB and non-GCB
subtypes of this disease have not yet been examined. In this study,
we aimed to clarify the clinicopathological features of localized
nasal/paranasal DLBCL.
Materials and Methods
Patients
We selected 39 Japanese patients diagnosed with localized
nasal/paranasal DLBCL between 1995 and 2010 and reviewed
our institution’s pathology department database to obtain the
medical records of these patients. We only evaluated localized
lymphomas, because the primary sites of advanced lymphomas
are difficult to determine. All 39 cases were diagnosed as primary
extranodal DLBCLs. Patients were defined as having extranodal
DLBCL when the disease was confined to one or more
extranodal sites and showed no (or only minor) nodal involve-
ment after the staging procedures [7,8]. This group of patients
was then compared with 39 patients with localized nodal
DLBCLs diagnosed at our institution [9]. The samples and the
medical records (clinical history, treatment and survival data)
used in our study was approved by the Institute Review Board
(IRB) at Okayama University. Written informed consent was
waived by our institutional review board, since our study was
limited to the use of excess human tissue samples and medical
records.
Histological Examination and Immunohistochemistry
Surgically resected or biopsied specimens of localized nasal/
paranasal DLBCLs were fixed in 10% formaldehyde and
embedded in paraffin. Serial sections (4 mm) were cut from each
paraffin-embedded tissue block, and several of these sections
were stained with hematoxylin. To subclassify the GCB- or non-
GCB- type of DLBCL, immunohistochemistry was performed on
formalin-fixed, paraffin-embedded sections using an automated
Bond Max stainer (Leica Biosystems, Melbourne, Australia). The
primary antibodies used were as follows: CD20 (L26, 1:200;
Novocastra, Newcastle-upon-Tyne, UK), CD3 epsilon (LN10,
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1:200; Novocastra), BCL6 (D8, 1:100; SantaCruz), CD5 (4C7,
1:100; Novocastra), GCET1 (RAM341, 1:100; Abcam), CD10
(56C6, 1:50; Novocastra), MUM1 (MUM1p, 1:50; Dako), FoxP1
(JC12, 1:500; LifeSpan Biosciences, Seattle, USA), and Ki-67
(MIB-1, 1:5000; Novocastra). For each section, 10 high-power
fields were recorded, quantitated, and averaged to calculate the
estimated percentage of positively immunostained cells. Negativ-
ity for CD10, BCL6, and MUM1 was defined as ,30%
positively stained tumor cells, and positivity was defined as
.30% positively stained tumor cells. As an exception, for Choi’s
algorithm, negativity for MUM1 was defined as ,80% positively
stained tumor cells, and positivity, as .80% positively stained
tumor cells. Negativity for GCET1 and FoxP1 staining was
defined as ,80% positively stained tumor cells, and positivity, as
.80% positively stained tumor cells. Ki-67 immunoreactivity
was evaluated semi-quantitatively by using the average estimated
percentage of positive cells in the 10 recorded high-power fields
[4].
Statistical Analysis
All data were analyzed using STATA software (version 9.0;
Stata Corp., College Station, TX, USA). Actuarial overall survival
curves were calculated using the Kaplan-Meier method, and
differences were examined using the log-rank test to determine
significant prognostic factors [10]. Overall survival was defined as
the time from diagnosis to death from any cause or to the last
follow-up visit.
Results
Characteristics of the Nasal/Paranasal DLBCL Cases
Table 1 and Table 2 summarize the characteristics of the
localized nasal/paranasal DLBCL patients. The median age of
the 39 patients was 76 years (range, 33–98 years). The patient
population comprised 21 men and 18 women. According to
Choi’s algorithm, 11 of the 39 patients (28%) were of the GCB-
type and 28 (72%) were of the non-GCB- type. According to
Hans’ algorithm, 11 (28%) were of the GCB- type and 28 of the
39 patients (72%) were of the non-GCB type (Table 3).
According to the Ann Arbor classification, 33 patients were at
clinical stage IE and 6 were at stage IIE. According to the
International Prognostic Index, 4 patients were at low- interme-
diate risk and 13 were at low risk. Histologically, all cases were
classified as DLBCL (Fig. 1). All patients were newly presenting
with no prior treatment history.
Phenotypic Features of the Localized Nasal/Paranasal
DLBCL Cases
Table 4 summarizes the phenotypic features of the localized
nasal/paranasal DLBCL patients. The B-cell immunophenotype
of the lymphomas was confirmed by immunoreactivity with
antibodies to CD20 in 39 cases. Although no cases were positive
for CD5, 8 (21%) were positive for CD10 and 25 (64%) were
positive for BCL6. For MUM1 staining, 28 cases (72%) were
positive according to Hans’ algorithm and 24 cases (62%) were
positive according to Choi’s algorithm. Furthermore, 29 cases
(74%) were positive for FoxP1 and 12 (31%) were positive for
GCET1. Of the 11 cases (28%) classified as GCB- type according
to Hans’ algorithm, 8 were CD10-positive cases (20%), and 3 were
CD10-negative, BCL6-positive, MUM1-negative cases (8%). Of
the 11 (28%) classified as GCB- type according to Choi’s
algorithm, 3 were GCET1-positive, MUM1-negative cases (8%);
5 were GCET1-negative, CD10-positive cases (13%); and 3
GCET1-negative, CD10-negative, BCL6-positive, FoxP1-negative
cases (8%). Of the 28 cases (72%) classified as the non-GCB- type
according to Hans’ algorithm, 12 were CD10-negative, BCL6-
negative cases (31%) and 16 were CD10-negative, BCL6-positive,
MUM1-positive cases (41%). Of the 28 cases (72%) classified as
the non-GCB- type according to Choi’s algorithm, 9 were
GCET1-positive, MUM1-positive cases (23%); 8 were GCET1-
negative, CD10-negative, BCL6-positive, FoxP1-positive cases
(20%); and 11 were GCET1-negative, CD10-negative, BCL6-
negative cases (28%) (Fig. 2). The non-GCB- type was dominant
according to both algorithms, but the prognosis for these cases was
good. Overall survival did not differ significantly between the non-
GCB type and GCB type groups (p = 0.57, Hans’ algorithm,
p = 0.99, Choi’s algorithm) (Fig. 3).
Therapeutic Response and Outcome
Follow-up clinical data were available for 28 patients. The
duration of follow-up ranged from 1 to 125 months (mean, 29
months). Fifteen patients were initially treated with chemother-
apy plus irradiation, 9 were treated with chemotherapy alone,
and 2 were treated with irradiation alone. Twenty-two patients
achieved complete remission. Although 7 patients relapsed, 3 of
Figure 1. Histological and immunohistochemical features. Diffuse infiltration and proliferation of large lymphoma cells (Hematoxylin–eosin
staining).
doi:10.1371/journal.pone.0057677.g001
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these patients achieved complete remission following alternative
chemotherapy. Salvage treatments for the 7 relapsed patients
were R-MFP (methotrexate, fluorouracil, low dose cisplatin, and
rituximab), R-THP-COP (cyclophosphamide, vincristine, pred-
nisolone, pirarubicin, and rituximab), R-MTX (methotrexate and
rituximab), and CHASER (cyclophosphamide, high dose cytar-
abine, dexamethasone, etoposide, and rituximab) plus radiation.
At the time of reporting, 16 patients were disease- free and 3
patients had died of the disease.
Comparison of the Clinicopathological Characteristics of
Localized Nasal/Paranasal DLBCL and Localized Nodal
DLBCL
The clinicopathological characteristics of nasal/paranasal
DLBCL and localized nodal DLBCL are summarized in Table 5.
Nasal/paranasal DLBCL patients showed good prognosis. The
slight difference in the overall survival between these patients and
patients with localized nodal DLBCL was not significant (p = 0.30)
(Fig. 4). Moreover, analysis using the x2-test revealed a significant
difference between the 2 groups with regard to age distribution
and immunophenotype. Localized nasal/paranasal DLBCL
patients were more likely to be more than 60 years old than
localized nodal DLBCL patients (p = 0.018). In addition, localized
nasal/paranasal DLBCL patients showed significantly higher
positivity for MUM1 than localized nodal DLBCL patients
according to Choi’s algorithm (p = 0.00023, x2-test).
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Table 2. Clinical characteristics of patients with localized
nasal/paranasal DLBCL.
Characteristic No. of patients (%)
Sex
Male 21(54)
Female 18(46)
Age (y), median (range) 76 (33–98)
Ann Arbor stage
I 33(85)
II 6(15)
LDH
Normal
Elevated
24(77)
7(23)
PS
0–1 15(79)
2 or more 4(21)
IPI
L-LI 27(96)
HI-H 1(4)
Treatment
chemotherapy 8(32)
chemotherapy+RT 15(60)
RT alone 2(8)
Complete Remission
yes 22(88)
no 3(12)
doi:10.1371/journal.pone.0057677.t002
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Discussion
DLBCL is the most frequent and aggressive lymphoma,
representing a heterogeneous group that includes de novo large B-
cell lymphomas, as well as transformed lymphomas from
follicular or mucosa-associated lymphoid tissue lymphomas
[11]. Recent studies have demonstrated that DLBCL can be
further subclassified into 2 major prognostic categories according
to Hans et al.: the GCB- type and the non-GCB- type [1,2].
However, Hans’ algorithm has been superseded by a new
algorithm devised by Choi et al., and results obtained using
Choi’s algorithm closely correlate with those of gene expression
profiling for predicting prognosis [5]. In general, the non-GCB-
type of DLBCL is associated with a significantly poorer prognosis
than the GCB- type [1]; however, it has recently been established
that this may not be true for extranodal DLBCL. Patients with
localized primary non-tonsillar oral DLBCL presented with a
Figure 2. Distribution of GCB and non-GCB type according to Hans et al. and Choi et al.
doi:10.1371/journal.pone.0057677.g002
Table 3. Clinical and phenotypic characteristics of patients with GCB-type and non-GCB-type DLBCL.
Total (n = 39) Hans’ algorithm P Choi’ algorithm p
GCB (n=11) non-GCB (n=28) GCB (n=11) non-GCB (n=28)
Sex (male/female) 21/18 6/5 15/13 0.96 6/5 14/14 0.80
Age (y), median (range) 76 (33–98) 75 (57–98) 77 (33–94) 0.61 77 (57–98) 76 (33–94) 0.98
Age .60 34/39 (87%) 10/11 (91%) 24/28 (86%) 0.66 10/11 (91%) 24/28 (86%) 0.66
PS .1 4/19 (21%) 0/5 (0%) 4/14 (29%) 0.18 0/5 (0%) 4/14 (29%) 0.18
B symptoms 1/29 (3%) 1/8 (13%) 0/21 (0%) 0.099 1/8 (13%) 0/21 (0%) 0.099
LDH .normal 7/31 (23%) 2/8 (25%) 5/23 (22%) 0.85 2/9 (22%) 5/22 (23%) 0.98
Median survival
(months)
23 (1–125+) 35 (11–125+) 20 (1–101+) 0.57 35 (11–48+) 23 (1–125+) 0.99
Immunophenotype
CD10 8/39 (21%) 8/11 (73%) 0/28 (0%) ,0.0001 6/11 (55%) 2/28 (7%) 0.00097
MUM1(Hans) 28/39 (72%) 5/11 (45%) 23/28 (82%) 0.022
MUM1(Choi) 24/39 (62%) 3/11 (27%) 21/28 (75%) 0.0058
BCL6 25/39 (64%) 9/11 (82%) 16/28 (57%) 0.15 10/11 (91%) 15/28 (54%) 0.029
FOXP1 29/39 (74%) 6/11 (55%) 23/28 (82%) 0.076
GCET1 12/39 (31%) 3/11 (27%) 9/28 (32%) 0.77
Abbreviations: GCB, germinal center B-cell; PS, performance status; BM, bone marrow; LDH, lactate dehydrogenase; FOXP1, forehead box protein 1; GCET1, germinal
center B-cell expressed transcript 1.
doi:10.1371/journal.pone.0057677.t003
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favorable clinical course despite having the non-GCB- type [6].
Similarly, in our study, the non-GCB- type of localized nasal/
paranasal DLBCL was the dominant type following subclassifi-
cation according to both algorithms, but the prognosis of these
patients was good. Moreover, the prognosis of localized nasal/
paranasal DLBCL was as good as that of primary cutaneous
DLBCL [12] (p = 0.10) (Fig. 5) and was statistically better than
that of other localized extranodal DLBCLs (CNS [13], testis
[14], and adrenal gland [15]) (p = 0.0002, p = 0.0012, and
p = 0.0044, respectively) (Fig. 6). Generally, extranodal non-
GCB-like DLBCLs are characterized by poor prognosis, and the
incidence of non-GCB- type DLBCLs among extranodal
DLBCLs is 83–100%, although this value differs according to
the organ of manifestation [16,17,18,19]. According to previous
reports, DLBCLs of the central nervous system [16], breast [17],
stomach [20], leg type [21], testis [18], and intravascular type
[19] are predominantly of the non-GCB- type, an observation
consistent with the finding in our study of localized nasal/
paranasal DLBCL cases. However, patients with CNS, breast,
and testicular DLBCL exhibit poor prognosis, regardless of the
localized disease [16,17,18,22]. As shown for primary cutaneous
B-cell lymphoma, findings of genes expression analysis suggest
that primary non-leg-type cutaneous DLBCL and primary
cutaneous DLBCL, leg type have expression profiles similar to
those of GCB- type and non-GCB- type DLBCLs, respectively
[23]. Therefore, primary non-leg-type cutaneous DLBCL is
predominantly associated with an excellent prognosis [12,24].
According to the recent World Health Organization (WHO)
classification, subsets of DLBCLs arising in peculiar extranodal
sites have been categorized as distinct disease subgroups (primary
DLBCLs of the CNS, primary cutaneous DLBCLs, leg-type) or
as distinct disease entities (primary mediastinal large B-cell
lymphoma), on the basis of specific clinical and/or pathologic
features [25,26]. When the cases in our study are included,
extranodal disease is common among DLBCL patients [27]. It is
thought that there are important clinical differences between
nodal and extranodal DLBCL and that the most reliable
distinction can be made in patients with stage I disease. For
these patients, extranodal DLBCL is independently associated
with poor survival [27]. Therefore, we also compared the
clinicopathological profiles of localized nasal/paranasal DLBCLs
with localized nodal DLBCLs. This analysis showed that
localized nasal/paranasal DLBCL was associated with good
prognosis and no difference was noted in the prognosis compared
with localized nodal DLBCL. In recent years, the use of
rituximab has improved the prognosis of DLBCL patients, and
CHOP (cyclophosphamide, adriamycin, vincristine, and prednis-
olone) therapy combined with rituximab (R-CHOP) is currently
a standard chemotherapy for DLBCL [28]. In our study, no
significant difference was noted in the number of patients treated
with rituximab between localized nasal/paranasal DLBCL and
localized nodal DLBCL patients (p = 0.24). Therefore, the
prognosis of localized nasal/paranasal DLBCLs was favorable
regardless of treatment with rituximab. In conclusion, the
prognosis of localized nasal/paranasal DLBCL patients was
good irrespective of the disease subclassification, although the
non-GCB- type of DLBCLs are usually thought to be associated
with a poor prognosis.
Figure 3. Kaplan–Meier plot showing overall survival for patients with localized nasal/paranasal DLBCL.
doi:10.1371/journal.pone.0057677.g003
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Table 4. Immunohistochemical findings of localized nasal/paranasal DLBCLs.
Patient
no. CD3 CD5 CD10 CD20
Ki-67 labeling
(%)
MUM1
(Hans)
MUM1
(Choi) BCL6 EBER FOXP1 GCET1
subtype
(Hans)
subtype
(Choi)
1 2 2 2 + 21 U.D. 2 2 2 + 2 Non-GCB Non-GCB
2 2 2 p+ + 43 2 2 + 2 + 2 GCB GCB
3 2 2 + + 43 2 2 + 2 2 2 GCB GCB
4 2 2 2 + 80 + + 2 2 + 2 Non-GCB Non-GCB
5 2 2 2 + 59 + + 2 2 + 2 Non-GCB Non-GCB
6 2 2 2 + 54 + + + 2 + 2 Non-GCB Non-GCB
7 2 2 2 + 71 + + + 2 + 2 Non-GCB Non-GCB
8 2 2 2 + 82 + + 2 2 + 2 Non-GCB Non-GCB
9 2 2 2 + 71 2 2 2 2 + 2 Non-GCB Non-GCB
10 2 2 2 + 61 + + + 2 2 + Non-GCB Non-GCB
11 2 2 2 + 50 + + + 2 + 2 Non-GCB Non-GCB
12 2 2 2 + 34 + + + 2 2 + Non-GCB Non-GCB
13 2 2 2 + 55 + + + 2 + + Non-GCB Non-GCB
14 2 2 2 + 70 + + + 2 + + Non-GCB Non-GCB
15 2 2 + + 64 + + 2 2 2 + GCB Non-GCB
16 2 2 2 + 33 2 2 + 2 2 + GCB GCB
17 2 2 2 + 61 + + 2 2 + + Non-GCB Non-GCB
18 2 2 2 + 72 + + 2 2 2 2 Non-GCB Non-GCB
19 2 2 2 + 63 + + + 2 2 2 Non-GCB GCB
20 2 2 2 + 67 2 2 + 2 2 2 GCB GCB
21 2 2 2 + 80 + + 2 2 2 2 Non-GCB Non-GCB
22 2 2 + + 80 + + 2 2 + 2 GCB GCB
23 2 2 + + 72 2 2 + 2 + + GCB GCB
24 2 2 + + 90 + + + 2 + 2 GCB GCB
25 2 2 2 + 73 2 2 + 2 + + GCB GCB
26 2 2 2 + 81 + + + 2 + 2 Non-GCB Non-GCB
27 2 2 2 + 52 + + + 2 + 2 Non-GCB Non-GCB
28 2 2 2 + 72 + 2 2 2 + 2 Non-GCB Non-GCB
29 2 2 + + 97 + + + 2 + + GCB Non-GCB
30 2 2 2 + 90 2 2 2 2 + 2 Non-GCB Non-GCB
31 2 2 + + 77 + 2 + 2 + 2 GCB GCB
32 2 2 2 + 49 2 2 2 2 + 2 Non-GCB Non-GCB
33 2 2 2 + 88 + + + 2 + + Non-GCB Non-GCB
34 2 2 2 + 54 + + + 2 + 2 Non-GCB Non-GCB
35 2 2 2 + 58 + 2 + 2 2 2 Non-GCB GCB
36 2 2 2 + 92 + 2 + 2 + 2 Non-GCB Non-GCB
37 2 2 2 + 61 2 + + 2 + 2 Non-GCB Non-GCB
38 2 2 2 + 90 + 2 2 2 + 2 Non-GCB Non-GCB
39 2 2 2 + 83 + + + 2 + + Non-GCB Non-GCB
EBER, Epstein–Barr virus-encoded small RNA; GCB, germinal center B-cell; FOXP1, forehead box protein 1; GCET1; germinal center B-cell expressed transcript 1.
doi:10.1371/journal.pone.0057677.t004
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Figure 4. Comparison of overall survival between localized nasal/paranasal DLBCL and localized nodal DLBCL.
doi:10.1371/journal.pone.0057677.g004
Table 5. Clinical and phenotypic characteristics of patients with localized nasal/paranasal DLBCL and localized nodal DLBCL.
localized nasal/paranasal DLBCL localized nodal DLBCL p
Total (n = 39) Total (n = 39)
Sex (male/female) 21/18 23/16 0.65
Age (y), median (range) 76 (33–98) 70 (33–79) 0.0010
Age .60 34/39 (87%) 25/39 (64%) 0.018
IPI : L-LI 27/28 (96%) 38/39 (97%) 0.81
Relapse 7/22 (32%) 16/39 (41%) 0.48
LDH .normal 7/31 (23%) 7/39 (18%) 0.63
Median survival (months) 23 (1–125+) 49 (4–146+) 0.30
Immunophenotype
CD10 8/39 (21%) 16/39 (41%) 0.050
MUM1(Hans) 28/39 (72%) 28/39 (72%) 1.0
MUM1(Choi) 24/39 (62%) 8/39 (21%) 0.00023
BCL6 25/39 (64%) 31/39 (79%) 0.13
FOXP1 29/39 (74%) 32/39 (82%) 0.41
GCET1 12/39 (31%) 17/39 (44%) 0.24
Abbreviations: GCB, germinal center B-cell; PS, performance status; LDH, lactate dehydrogenase.
doi:10.1371/journal.pone.0057677.t005
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Figure 5. Comparison of overall survival between localized nasal/paranasal DLBCL and localized skin DLBCL.
doi:10.1371/journal.pone.0057677.g005
Figure 6. Comparison of overall survival between localized nasal/paranasal DLBCL and localized adrenal, CNS, and testicular
DLBCLs.
doi:10.1371/journal.pone.0057677.g006
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